INTRODUCTION
Glycosylphosphatidylinositol (GPI)-specific phospholipases have intriguing effects on cell physiology [1] [2] [3] [4] . Phosphatidylinositolspecific phospholipase C (PI-PLC) from Bacillus spp. and GPI-specific phospholipase C (GPI-PLC) from Trypanosoma brucei are widely used for studying the biochemistry and cell biology of GPIs both in itro and in i o [5] [6] [7] [8] . Consequently, understanding the biochemical and physiological roles of these enzymes is important. PI-PLC from B. cereus lacks cysteine residues [9] , whereas GPI-PLC from T. brucei has eight cysteines [10, 11] .
Thiol reagents are routinely used for determining whether (or not) cysteine residues are important for protein activity. For polypeptides that contain Cys residues, it is generally thought that inactivation of their function arises from covalent modification of the polypeptide. While these concepts may be true in many instances, other possibilities may be worthy of consideration.
First, inactivation of a protein by a thiol reagent may not necessarily mean that a Cys residue is essential for function. A case in point is GPI-PLC from T. brucei ; the enzyme is inactivated by p-chloromercuriphenylsulphonate ( pCMPS) [12, 13] , yet there is no evidence that a Cys is critical for catalysis [14] . Recently, Cys-80 was identified as the putative target of pCMPS [15] . Cys-80 is within a peptide stretch that has sequence similarity to PI-PLC from Bacillus species [16, 17] . A Cys-80 Phe mutant of T. brucei GPI-PLC lacks enzyme activity, while a Abbreviations used : DMG, dimyristoylglycerol ; GPI, glycosylphosphatidylinositol ; GPI-PLC, glycosylphosphatidylinositol-specific phospholipase C ; β-ME, β-mercaptoethanol ; mf VSG, membrane-form variant surface glycoprotein ; pCMPS, p-chloromercuriphenylsulphonate ; PI, phosphatidylinositol ; PI-PLC, phosphatidylinositol-specific phospholipase C. 1 These authors contributed equally to this work. 2 To whom correspondence should be addressed (e-mail mensawil!cb.uga.edu).
similar protocol. Equimolar β-mercaptoethanol ( β-ME) reversed the inhibition of PI-PLC activity in a pCMPS : PI-PLC complex. For T. brucei GPI-PLC, however, ultrafiltration of the pCMPS : GI-PLC complex and addition of a large excess of β-ME was necessary for partial recovery of enzyme activity. Thus T. brucei GPI-PLC is susceptible to inactivation by covalent modification with pCMPS, whereas PI-PLC is not. Kinetic analysis indicated that pCMPS was a competitive inhibitor of PI-PLC when a GPI was a substrate. Curiously, with phosphatidylinositol as substrate, inhibition was no longer competitive. These data suggest that pCMPS is a glyco-mimetic that occupies the glycan binding site of PI-PLC, from where, depending on the substrate, it inhibits catalysis allosterically or competitively.
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Cys-80 Ala mutant remains active, but is highly resistant to inactivation by pCMPS [15] . Coupled with the fact that Gln-81 mutants of GPI-PLC were inactive, two factors were thought to account for the inactivation of GPI-PLC by pCMPS : (1) the proximity of Cys-80 to the putative active site, and (2) the conversion of Cys-80 into a bulky cysteinylmercuriphenylsulphonate adduct that could sterically hinder the active site [15] . Secondly, thiol reagents could inhibit the function of proteins that do not contain cysteine residues. An example of such a protein is PI-PLC from Bacillus spp. [18] . A logical interpretation of such data would be that the thiol reagent reacted with a non-cysteine side chain in the polypeptide.
We found that Bacillus cereus PI-PLC is inhibited by pCMPS, as reported previously [18] . To explore how a thiol reagent inhibited a Cys-less protein, numerous hypotheses were examined. Several lines of evidence lead to a conclusion that pCMPS is a glyco-mimetic that competitively inhibits PI-PLC by binding to the glycan recognition site on the enzyme. In related studies, we established that pCMPS inactivates T. brucei GPI-PLC by covalent modification.
MATERIALS AND METHODS

Reagents
pCMPS, CuSO % , HgCl # and β-mercaptoethanol ( β-ME) were obtained from Sigma Chemical Co. (St. Louis, MO, U.S.A.). BSA was from New England BioLabs (Beverly, MA, U.S.A.). 
Figure 1 Inhibition of B. cereus PI-PLC and T. brucei GPI-PLC by pCMPS
GPI-PLC assays
Recombinant T. brucei GPI-PLC from was purified from Escherichia coli [19] . B. cereus PI-PLC (600 units\mg) was a gift from Dr Mary Roberts (Boston University, Boston, MA, U.S.A. 
Removal of unreacted pCMPS
To prepare Centricon-10 ultrafiltration units for use, sites for non-specific protein adsorption were blocked with 1 ml of BSA (50 µg\ml in water). After incubation of the phospholipase with pCMPS (in 20 µl), the mixture was diluted with 980 µl of the appropriate buffer. The diluted mixture was centrifuged (5000 g, 4 mC, 2.5 h) through a Centricon-10 membrane. Approx. 50 µl of ' retentate ' was obtained for each enzyme, 5 µl of which was used per assay.
Modification of [ 3 H]mf VSG with pCMPS
[$H]mf VSG (20 µg) was incubated with (or without) pCMPS (2.5 mM final) in 20 µl of GPI-PLC buffer at 37 mC for 10 min, after which 980 µl of chilled GPI-PLC buffer was added.
[$H]mf VSG was recovered in the retentate after ultrafiltration through a Centricon-10 membrane (5000 g, 4 mC, 2.5 h). A sample of 2 µg of pCMPS-treated [$H]mf VSG was used in specified GPI-cleavage assays. [9] . The mixture was dried under nitrogen gas and the PI was resuspended in 1 ml of PI-PLC buffer. The suspension was sonicated for 5 min in a Vibra Cell sonicator (Sonics and Materials, Pittsburgh, PA, U.S.A.) with amplitude at 20, and the pulser off. The substrate was stored at k20 mC and thawed just before use.
Inhibition of PI-PLC and GPI-PLC
[ 3 H]PI digestion by PI-PLC and its inhibition by pCMPS, CuSO 4 and HgCl 2
B. cereus PI-PLC (0.053 ng in 10 µl of PI-PLC buffer ; 0.15 nM final concentration) was incubated with pCMPS (0.5-20 µl of 10 mM stock, in PI-PLC buffer) at 37 mC for 10 min [9] . (The 
Figure 3 Inhibition of T. brucei GPI-PLC by pCMPS is not relieved by ultrafiltration : pCMPS-treated mf VSG is a good substrate for GPI-PLC
(A) Effect of filtration of a GPI-PLC : p CMPS complex on enzyme activity. T. brucei GPI-PLC (25 nM) was preincubated with or without p CMPS (5 mM). The mixture was filtered through a Centricon-10 membrane. A portion of the retentate containing GPI-PLC (2.5 nM) was used to cleave H]mf VSG was used as substrate for GPI-PLC. The enzyme itself had either been treated with p CMPS and filtered, or had never been exposed to the thiol reagent before filtration (see A).
Reversal of PI-PLC inhibition by EDTA and β-ME
EDTA (5-50 µM) or β-ME (10-100 µM) was added before incubation of PI-PLC with either pCMPS or HgCl # . Following addition of [$H]mf VSG, the mixture was incubated at 37 mC for 30 min. The reaction (40 µl final volume) was terminated by addition of 500 µl of water-saturated n-butanol, and centrifuged for 2 min (14 000 g, 25 mC). A 400 µl aliquot of the upper phase was recovered for scintillation counting.
Interfacial kinetics
The scooting model of kinetic analysis (reviewed in [22] ) was used because the substrates, [$H]mf VSG and [$H]PI, are cleaved at the interface between the aqueous solution and detergent micelles. The effective inhibitor concentration at the micelle interface was expressed as a ratio of the mole fraction of inhibitor (X i ) to the mole fraction of the remainder of the components of the reaction mixture (1kX i ), including substrate, inhibitor and detergent. Plots of V o \V i against X i \(1kX i ) (where V o is the reaction rate in the absence of inhibitor and V i is the reaction rate in the presence of inhibitor) were obtained. (2) when X i l 0, V o \V i is close to 1 [22, 23] . If either condition is not met, the points are fitted with an exponential curve function of Cricket Graph III version 1.5.3 (Computer Associates International, Inc., Islandia, NY, U.S.A.), and the inhibition is characterized as not competitive.
RESULTS
pCMPS inhibits a cysteine-less PI-PLC from B. cereus
PI-PLC from B. cereus does not contain cysteine residues [18] , yet the enzyme's digestion of GPI was inhibited by the thiol reagent pCMPS ( Figure 1A ). The IC &! for the inhibition of PI-PLC by pCMPS was 0.3 mM, and 90 % inhibition (IC *! ) was obtained with 1 mM pCMPS.
Since [$H]mf VSG contains cysteine residues within the protein portion [24] , inhibition of PI-PLC activity could arise from reaction of pCMPS with the substrate instead of with PI-PLC. This possibility was checked with two approaches. In the first protocol, pCMPS-treated [ Figure 1B) . The IC &! of pCMPS was 0.3 mM (Figure 1B) , similar to the value obtained when the GPI-anchored [$H]mf VSG was substrate ( Figure 1A) . The simplest interpretation of these data is that pCMPS interacts directly with PI-PLC during inhibition of enzyme activity.
Inhibition of a Cys-less PI-PLC by a thiol reagent was intriguing. Therefore we investigated possible mechanisms by which pCMPS might act on the phospholipase C. We tested a hypothesis that inhibition of PI-PLC resulted from non-covalent interactions between the enzyme and pCMPS. For this, the protein was pre-exposed to the inhibitor, and residual pCMPS (0.415 kDa) was removed by ultrafiltration before assay of the ' modified ' enzyme obtained in the retentate (Figure 2 ). In principle, enzyme activity would be inhibited if an adduct had formed between PI-PLC and pCMPS, whereas little loss of activity would be observed if no covalent adduct was created during the preincubation. Ultrafiltration of the PI-PLC : pCMPS complex resulted in loss of inhibition : PI-PLC activity was stimulated 10-fold (compare activity before and after filtration of pCMPStreated PI-PLC ; Figure 2 ). These data indicate that pCMPS inhibits PI-PLC without covalently modifying the enzyme.
GPI-PLC from T. brucei : removal of unreacted pCMPS fails to reverse inhibition
GPI-PLC from T. brucei contains eight cysteine residues [10, 11] , one of which appears to be at the enzyme active site [15] . The enzyme activity was inhibited completely by 5 mM pCMPS ( Figure 1A) . The IC &! and IC *! for pCMPS were 0.3 mM and 2 mM respectively.
We assessed whether inhibition of GPI-PLC was correlated with covalent modification of the enzyme by pCMPS. When GPI-PLC was pretreated with pCMPS, which was subsequently ' removed ' by ultrafiltration, no re-activation of enzyme activity occurred ( Figure 3A) Figures 3A  and 3B ). This degree of inhibition is expected if the filtered [$H]mf VSG contained 13 µM unreacted pCMPS [ Figure 1A ; estimated from an initial 5 mM pCMPS, dilution before the filtration, and the final volume in the retentate (detailed in the Materials and methods section)]. We surmise that GPI-PLC, and not mf VSG, is the major target of pCMPS.
B. cereus PI-PLC : equimolar β-ME reverses inhibition by pCMPS
Further evidence for the non-covalent nature of the interaction between B. cereus PI-PLC and pCMPS was acquired by examining the effect of β-ME on enzyme inhibition ( β-ME can react with pCMPS). PI-PLC was treated in two temporal stages, first with pCMPS (2 mM final) and then with β-ME (2 mM). Substrate was added in the third stage, and GPI digestion was determined.
Figure 4 Equimolar β-ME counteracts inhibition of B. cereus PI-PLC by pCMPS
(A) Preincubation of PI-PLC with p CMPS prior to β-ME addition. PI-PLC (0.85 ng, 2.5 nM) was first treated with 2 mM p CMPS (37 mC, 10 min), then β-ME (various concentrations) was added (37 mC, 10 min). [ 3 H]mf VSG (2 µg) was introduced, and the mixture was incubated at 37 mC for 10 min. Released [ 3 H]DMG was quantified. (B) Exposure of p CMPS to β-ME before introduction of PI-PLC. p CMPS was pretreated with different concentrations of β-ME. PI-PLC was then introduced into the mixture. [ 3 H]mf VSG was added finally, and the solution was incubated at 37 mC for 10 min. Released [ 3 H]DMG was quantified as described in the legend to Figure 1 .
Although introduced after exposure of the enzyme to pCMPS, β-ME reversed the inhibition of PI-PLC by the thiol reagent ( Figure 4A ). [By itself β-ME does not activate PI-PLC ( Figure 4A ).] To test whether β-ME could protect PI-PLC from inhibition by pCMPS, pCMPS was preincubated with β-ME before the addition of PI-PLC and substrate digestion. Equimolar β-ME (i.e. with respect to pCMPS) counteracted pCMPS completely ( Figure 4B ), but less than stoichiometric amounts failed to protect PI-PLC. This observation suggests that a ' complex ' formed between β-ME and pCMPS cannot inhibit PI-PLC ( Figure 4B ).
T. brucei GPI-PLC : excess β-ME is required to protect the enzyme from pCMPS
The possibility that β-ME might reverse the inactivation of T. brucei GPI-PLC by pCMPS was investigated. GPI-PLC was treated with 5 mM pCMPS prior to the addition of various
Figure 5 Effect of β-ME on pCMPS-mediated inhibition of T. brucei GPI-PLC
(A) Equimolar β-ME fails to reverse inhibition of T. brucei GPI-PLC by p CMPS. GPI-PLC (2.5 nM) was incubated with 5 mM p CMPS before addition of different concentrations of β-ME. [ 3 H]mf VSG was added, and the reaction was incubated at 37 mC for 10 min. Released [ 3 H]DMG was quantified. (B) Equimolar β-ME partially protects GPI-PLC from inhibition by p CMPS. p CMPS (5 mM) was first incubated with different concentrations of β-ME. GPI-PLC (2.5 nM) was added, followed by [ 3 H]mf VSG, whose digestion was carried out at 37 mC for 10 min. [ 3 H]DMG was quantified after extraction into n-butanol. (C) β-ME acts on p CMPSmodified GPI-PLC to re-activate enzyme activity. T. brucei GPI-PLC (25 nM) was preincubated with or without 5 mM p CMPS at 37 mC for 10 min. The mixture was filtered through amounts of β-ME. [ β-ME alone stimulated GPI-PLC 2-3-fold ( Figure 5A ).] An equimolar amount (i.e. with respect to pCMPS) of β-ME failed to restore GPI-PLC activity ( Figure 5A) . A 10-fold excess of β-ME led to recovery of 50 % of the maximal GPI-PLC activity (i.e. with β-ME). When pCMPS was preincubated with β-ME before addition to GPI-PLC, equimolar β-ME could not protect GPI-PLC from inhibition by pCMPS ( Figure 5B ) : only 13 % of the maximal activity was recovered. A 2-fold excess, at least, of β-ME was needed in preincubations with pCMPS to fully protect GPI-PLC ( Figure 5B ).
Centricon-10 (stage 1). GPI-PLC (25 nM) from the Centricon-10 retentate was exposed to various concentrations of β-ME at 37 mC for 10 min (stage 2). [ 3 H]mf VSG was added, and the reaction was incubated at 37 mC for 10 min for GPI cleavage. Released We tested a hypothesis that the β-ME-mediated reversal of pCMPS-dependent inhibition was the result of reaction of the reducing agent with pCMPS-modified GPI-PLC. To this end, GPI-PLC was first treated with pCMPS (5 mM) and the complex was filtered through a Centricon-10 membrane. GPI-PLC in the retentate was treated with various amounts of β-ME ( Figure 5C ). β-ME at 1 mM restored 50 % of GPI-PLC activity, and 5 mM was sufficient for 100 % activity. In the presence of 50 mM β-ME, GPI-PLC activity was stimulated slightly (i.e. activity was above the basal level observed in the absence of pCMPS) ( Figure 5C ).
When GPI-PLC was treated first with β-ME and the filtered enzyme studied, 1 mM pCMPS inhibited the enzyme by 80 % (results not shown). Thus β-ME does not permanently alter the biochemical properties of recombinant GPI-PLC : protection conferred by β-ME against pCMPS requires the continued presence of the reducing agent.
Together, these data indicate that pCMPS, in contrast with its mode of action on B. cereus PI-PLC, modifies T. brucei GPI-PLC covalently. Consistent with this conclusion, a large excess of reducing agent is needed to restore partial enzyme activity to a pCMPS : GPI-PLC adduct.
pCMPS is a competitive inhibitor of B. cereus PI-PLC
The absence of covalent modification during the inhibition of PI-PLC by pCMPS made it possible to determine the nature of the inhibition by the thiol reagent. Interfacial kinetic analysis (reviewed in [22] ) was chosen for this aspect of the work, since PI-PLC interacts with its substrates at the boundary between detergent micelles and the aqueous medium. The effective inhibitor concentration at the micelle interface was expressed as the ratio of the mole fraction of inhibitor (X i ) to the mole fraction of the remainder of the components of the reaction mixture (1kX i ). Plots of V o \V i against X i \(1kX i ) (where V o is the reaction rate in the absence of inhibitor and V i is the reaction rate in the presence of inhibitor) [25] are presented ( Figure 6 ). pCMPS proved to be a competitive inhibitor of the PI-PLCcatalysed digestion of [$H]mf VSG ( Figure 6A ). In control experiments, inhibition of T. brucei GPI-PLC by SDS did not occur competitively ; a linear curve fit to the data failed to satisfy the required conditions (see above). An exponential curve fit for the inhibition by SDS is presented ( Figure 6B) . Surprisingly, when [$H]PI was used as substrate, the linear equation obtained for the data was y l 6.105xk1.831, and r# was 0.886 (i.e. less than 0.9) (graph not shown). When X i \(1kX i ) l 0, V o \V i l k1.831 (this value deviates significantly from the expected value of 1.0). A much better fit of the data was obtained with the exponential equation y l 0.893i10! .&&*x (r# l 0.994) ( Figure 6C ). From the curve, V o \V i l 0.893 (i.e. close to 1) when X i \(1kX i ) l 0. We conclude that when [$H]PI is the substrate, pCMPS is not a competitive inhibitor of PI-PLC.
EDTA distinguishes between pCMPS-and Hg 2 + -mediated inhibition of B. cereus PI-PLC
Mercury is a component of pCMPS. Consequently we considered the possibility that inhibition of PI-PLC by the thiol reagent was due to Hg# + contamination of commercial pCMPS (the manufacturer's product analysis sheet did not report the presence of Hg# + ). We presumed that between 0.1 % and 1 % of Hg in pCMPS was Hg# + ion. Since 2 mM pCMPS inhibited B. cereus PI-PLC completely ( Figures 1A and 1B) , we tested whether 2 µM Hg# + (i.e. 0.1 % of the pCMPS concentration), presented as the chloride salt, would inhibit PI-PLC. (Micromolar chloride ions, as the sodium salt, do not inhibit PI-PLC activity.) HgCl # was a potent inhibitor of PI-PLC ; 0.6 µM inhibited PI-PLC by 50 % (Figure 7A ), as reported previously [18] . In control experiments, CuSO % inhibited PI-PLC feebly ( Figure 7B ). Although 5 µM CuSO % decreased PI-PLC activity by 50 %, the susceptibility of the enzyme to Cu# + tapered off ; significant ac-Thiol reagent inhibition of GPI-specific phospholipases tivity remained in 30 µM CuSO % (results not shown). Thus Cu# + is not as good an inhibitor of PI-PLC as Hg# + .
EDTA binds to metal ions. We therefore tested whether it could counteract the effects of Hg# + on PI-PLC. When PI-PLC was preincubated with 10 µM Hg# + , equimolar EDTA blocked the inhibition of PI-PLC ( Figure 7C ). This result is consistent with successful chelation of Hg# + by EDTA.
The effect of EDTA on the pCMPS-mediated inhibition of PI-PLC was different from that reported for Hg# + -mediated inhibition ( Figure 7C ). Quantities of EDTA (5 µM and above) similar to those that rescued PI-PLC from Hg# + -mediated inhibition failed to shield PI-PLC from pCMPS ( Figure 7C) . If the effect of pCMPS on PI-PLC was due to contamination by 0.1 % Hg# + , 5 µM EDTA would reverse the inhibition. Yet 50 µM EDTA could not prevent the pCMPS-mediated inhibition of PI-PLC. These results indicate that the pathway of Hg# + -mediated inhibition of PI-PLC is distinct from the mechanism employed by pCMPS. More importantly, the data indicate that inhibition of PI-PLC by pCMPS is not the result of Hg# + contamination of the thiol reagent.
DISCUSSION
GPI-specific phospholipases are used routinely for the demonstration of GPI anchoring of proteins and polysaccharides to biological membranes [26] , and as membrane-impermeable ' probes ' of GPI synthesis in i o and in itro [7, [27] [28] [29] . The enzymes have been used to construct transgenic GPI-deficient cells to explore the biological roles of GPIs [5, 6, 30] . These diverse uses of this unique class of phospholipases call for clear understanding of the conditions that affect their activity in whole cells and in itro.
The participation of cysteine residues in biochemical and biological events is frequently revealed initially by susceptibility to thiol reagents (e.g. pCMPS or N-ethylmaleimide). Some recent cases involving membrane-active proteins highlight interesting developments in the field. Calcium-insensitive cytosolic phospholipase A # is inhibited by N-ethylmaleimide, yet mutagenesis studies indicate that none of the nine cysteine residues in the protein are critical for activity [31] . GPI-PLC from T. brucei is inhibited by thiol reagents [12, 32, 33] , but no single cysteine is indispensable for enzyme activity [12, 33, 34] . Similarly, Cys residues in Na + \dicarboxylate co-transporter-1 are not needed for function, although activity of the protein is blocked by p-chloromercuribenzenesulphonate [35] . At the other end of the spectrum, a Cys-less PI-PLC can be inhibited by a thiol reagent (Figure 1 ) [18] .
In an attempt to gain understanding of how pCMPS affects B. cereus PI-PLC, our first objective was to determine whether the inhibition required covalent modification of the enzyme. In experiments where a preformed PI-PLC : pCMPS complex was resolved by ultrafiltration into enzyme (in the retentate) and free pCMPS (in the filtrate), most of the enzyme activity was recovered ( Figures 2 and 4) . This finding suggested that inhibition of PI-PLC by pCMPS did not result from covalent modification. In a control experiment with T. brucei GPI-PLC, activity in a pCMPStreated enzyme could not be recovered in the retentate by following the protocols described for PI-PLC (Figure 3) .
Further evidence for the absence of covalent modification during inhibition of B. cereus PI-PLC activity by pCMPS was obtained from staged incubations of the enzyme with either pCMPS or the reducing agent β-ME. After pretreatment of PI-PLC with pCMPS, the amount of β-ME needed to ' reverse ' the inhibition was equimolar to the concentration of pCMPS (Figure 4) . One would not expect such low (relative) stoichiometry for the reducing agent if the enzyme had been modified covalently (see data on T. brucei GPI-PLC below). These data support the earlier conclusion (from the ultrafiltration experiments) that pCMPS does not modify B. cereus PI-PLC covalently.
With regard to the use of PI-PLC for analysis of GPIs, our observations suggest the following. First, it may be beneficial to avoid pCMPS in the preparation of substrates from cell lysates. Secondly, inclusion of EDTA (50 µM) in PI-PLC buffers will be beneficial ; EDTA is likely to keep the enzyme active in cases where small amounts of metal ions may interfere with its action on GPIs. Thirdly, if the use of thiol reagents is unavoidable in substrate preparation, investigators are encouraged to include β-ME in the reaction buffer to reverse inhibition by the thiol reagents.
Unlike B. cereus PI-PLC, T. brucei GPI-PLC displayed properties of a protein that was covalently modified by pCMPS. Following exposure to pCMPS, a 5-10-fold excess of β-ME was needed to recover significant enzyme activity ( Figure 5A) . A preformed pCMPS : GPI-PLC complex had no activity even after ultrafiltration to remove pCMPS ( Figure 5C ). Recovery of activity in the filtered enzyme (2.5 nM in the reaction) required a 2.5i10$-fold excess (1 mM) of β-ME ( Figure 5C ). Even then, 50 mM β-ME failed to restore full activity to GPI-PLC (results not shown).
The nature of the inhibition of B. cereus PI-PLC by pCMPS ( Figure 6 ) is captivating. pCMPS has affinity for the GPI binding site of PI-PLC, since it is a competitive inhibitor of mf VSG digestion ( Figure 6A ). Curiously, with PI as a substrate the type of inhibition changes ; it is no longer competitive ( Figure 6B ). The major difference between the two substrates (i.e. PI and GPI) is the presence of the ethanolamine (EtN)-phosphoglycan (EtN-P-Man $ -GlcN) group [27] on the GPI of mf VSG. So how does one reconcile the different modes of pCMPS-mediated inhibition ?
PI-PLC binds to both the inositol and the glycan moieties of the substrate [36, 37] , and a GPI is a better substrate for PI-PLC than is PI [38] [39] [40] . Scission of the phosphodiester bond at the inositol 1-position is influenced by glycan recognition. Surprisingly, data from crystal structures indicate that the myo-inositol headgroup of PI is not recognized within the same pocket where the glycan is bound to PI-PLC. myo-Inositol makes several contacts within a relatively deep groove in PI-PLC [37] , but the glycan recognition site extends on shallow grooves along the surface of the protein (reviewed in [41] ). From these considerations, an inhibitor that occupies the myo-inositol site need not interfere with another molecule binding to the glycan binding site. Our data suggest that pCMPS binds the glycan recognition site on PI-PLC. Thus, when a GPI is the substrate, the mode of inhibition is competitive, because of the glycan on that substrate. However, PI is recognized solely at the myo-inositol site, meaning that PI does not compete with pCMPS, which, acting as a glycomimetic compound, is at the glycan recognition site of PI-PLC. Thus, when PI is the substrate, pCMPS occupancy of the glycan binding site lowers rates of catalysis allosterically.
Our data on B. cereus PI-PLC and similar results [17] call for caution in the interpretation of observations from inhibition of protein function by thiol reagents. Where possible, supporting evidence for covalent modification (e.g. resuscitation with a reducing agent after removal of the inhibitor) can strengthen conclusions about how the thiol reagents act on the polypeptides. The experimental strategies employed in the present study point to some rapid biochemical approaches for distinguishing between covalent and non-covalent inhibition of protein function by thiol reagents. Eventually, these biochemical studies can be complemented with mutagenesis of the cysteine residues when genes for the proteins in question become available.
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